"The market went a little bearish toward the end of last year, and [an IPO] came off our radar as something we might attempt."
Robert Clarke, CEO, Pulmatrix Inc., on the firm's reverse merger strategy with Ruthigen Inc.

"Patients shouldn't have to wait months or years for the Drug Enforcement Agency to reach the same conclusion as the Food and Drug Administration."
Rep. Joe Pitts (R-Pa.), sponsor of a bill leading to House approval of Improving Regulatory Transparency for New Medical Therapies Act, H.R. 639

"One of the major reasons why we were attracted to Singapore is that they have the extreme phenotypes. There is a population of South Indians, Malays, Chinese . . . people don't move out of that area so you can monitor them over time."
Ratan Bhat, head of strategy and externalization at Astrazeneca's Cardiovascular & Metabolic Diseases Innovative Medicines and Early Development unit, on Astrazeneca forging an academic collaboration with leading Singaporean research institutes giving them access to a population that can provide insights into heart failure

"Given that there's no approved therapy for treating EB, either in the U.S. or abroad, we have been approached about partnering by a lot of companies from different regions around the world. We're just trying to focus on getting our phase III up and going."
Robert Ryan, president and CEO of Scioderm Inc., which moved lead compound, Zorblisa (SD-101) into a phase III registration study in epidermolysis bullosa (EB), a rare genetic connective tissue disorder

"By enrolling 75 percent of our patients in China and 25 percent in the U.S., we can actually finish enrolling patients in the phase III trial in one year and follow up in another year, so we can finish this trial in two years. Usually it takes four to five years for a global phase III trial."
Lan Huang, founder, chairman and CEO of Beyondspring Pharmaceuticals Inc., discussing the strategy for the phase III program of lead compound, plinabulin, in non-small-cell lung cancer